How should I evaluate and manage a 66-year-old female with diabetes, chronic kidney disease stage 3, obesity, recent bacterial vaginosis treated with metronidazole, spiking fevers despite cefepime and vancomycin, negative blood cultures, and a COVID‑19 infection diagnosed two weeks ago?

Evaluation and Management of Persistent Fever Despite Broad-Spectrum Antibiotics

Stop cefepime immediately due to high risk of neurotoxicity in this CKD stage 3 patient, and systematically search for non-bacterial sources of fever given negative blood cultures and recent COVID-19 infection. 1

Immediate Action: Discontinue Cefepime

Your patient is at critical risk for cefepime-induced neurotoxicity. The FDA label explicitly warns that serious adverse reactions including encephalopathy, confusion, hallucinations, myoclonus, seizures, and nonconvulsive status epilepticus occur predominantly in patients with renal impairment—even when doses are appropriately adjusted for CKD 1. With CKD stage 3, continued cefepime despite persistent fevers without identified bacterial source is unjustifiable and dangerous.

Reassess the Fever Source

COVID-19 as Primary Driver

This patient is 2 weeks post-COVID diagnosis—precisely the timeframe when the inflammatory phase peaks. Guidelines emphasize that bacterial co-infections in COVID-19 patients are uncommon (only 3.5% on admission), and secondary bacterial infections occur in up to 20% but primarily in severely ill/ICU patients 2.

Key point: Negative blood cultures after 48 hours on broad-spectrum antibiotics strongly argue against bacterial infection. The 2021 European guideline recommends stopping antibiotics when cultures obtained before empirical therapy show no pathogens after 48 hours 2.

Systematic Fever Workup Required

Look for these specific alternative sources:

• Drug fever: Both cefepime and vancomycin can cause this; metronidazole less commonly 1, 3
• COVID-19 inflammatory phase: Persistent fever 2 weeks out suggests ongoing cytokine-mediated inflammation rather than bacterial superinfection
• Fungal infection: Her diabetes, obesity, recent antibiotics (metronidazole for BV), and now prolonged broad-spectrum therapy create perfect conditions for invasive candidiasis. Diabetic patients have specific immune aberrations (elevated Th2, blunted Th1 response) predisposing to fungal infections 4
• Recurrent/complicated BV: Metronidazole failure occurs in up to 50% within one year; biofilm formation may protect bacteria from antimicrobials 5, 6. However, BV alone doesn't cause spiking fevers
• Urinary tract infection: Diabetics with CKD have increased UTI risk and may harbor resistant organisms or fungal UTI 4
• Clostridioides difficile: Recent metronidazole, now cefepime/vancomycin—check for diarrhea and consider testing 1

Recommended Diagnostic Algorithm

1. Immediately: Check for cefepime neurotoxicity signs (confusion, myoclonus, altered mental status)
2. Cultures:
   • Repeat blood cultures (fungal and bacterial)
   • Urine culture with fungal culture
   • Sputum culture if respiratory symptoms
   • Consider vaginal culture if ongoing symptoms
3. Imaging: Chest CT to assess for organizing pneumonia, pulmonary embolism, or fungal infection
4. Labs:
   • Procalcitonin (if elevated, supports bacterial infection; if low/normal, supports stopping antibiotics) 2
   • Inflammatory markers (CRP, ferritin, D-dimer) to assess COVID-19 inflammatory phase
   • Beta-D-glucan and galactomannan for invasive fungal infection
   • C. difficile testing

Antibiotic Management Strategy

Stop cefepime now. Continue vancomycin only if there's specific concern for MRSA (skin/soft tissue source, positive nasal screen, or local epidemiology), otherwise stop it too 2.

If you identify a specific bacterial source:

• Healthcare-associated pneumonia/VAP: Use local antibiogram to cover S. aureus, Enterobacterales, P. aeruginosa, but avoid cefepime—consider meropenem with renal dosing 2
• Complicated UTI: Tailor to culture results; diabetics need 7-14 days, not the standard 5 days 4

Special Considerations for This Patient

Diabetes + CKD + Recent Metronidazole

This combination creates vulnerability to:

• Recurrent candidiasis: Requires tight glycemic control plus prolonged intermittent antifungal therapy 4. If recurrent BV is actually candidiasis, she needs fluconazole (dose-adjusted for CKD), not more metronidazole
• Metronidazole accumulation: With CKD, metronidazole metabolites accumulate, potentially causing neuropathy 3

COVID-19 + Obesity + Diabetes

These are established risk factors for severe COVID-19 and prolonged inflammatory response 7. Persistent fever may represent:

• Ongoing viral inflammation (not requiring antibiotics)
• Organizing pneumonia (may need corticosteroids if not already given)
• Thromboembolic complications (check D-dimer, consider imaging)

Critical Pitfall to Avoid

Do not continue empiric broad-spectrum antibiotics "just in case" with negative cultures beyond 48-72 hours. This approach:

• Increases antibiotic resistance
• Causes drug toxicity (especially cefepime neurotoxicity in CKD)
• Promotes C. difficile and fungal superinfection
• Obscures the true diagnosis

The 2021 COVID-19 antibiotic guideline explicitly recommends stopping antibiotics when pre-treatment cultures are negative at 48 hours 2. Your patient has now exceeded this timeframe with no bacterial growth.

Bottom Line Algorithm

1. Stop cefepime immediately (neurotoxicity risk)
2. Reassess vancomycin necessity (stop if no MRSA indication)
3. Obtain fungal cultures and markers (high-risk patient)
4. Check procalcitonin (if low, supports non-bacterial fever)
5. Image chest (assess COVID-19 complications vs. fungal infection)
6. Consider empiric antifungal if high clinical suspicion while awaiting cultures
7. Optimize diabetes control (directly impacts infection risk and outcomes) 8